Results 1 to 10 of about 1,081,297 (374)

Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines

Human Vaccines & Immunotherapeutics, 2021
The universal administration of pneumococcal conjugate vaccines (PCVs) had been demonstrated as an effective way to prevent Streptococcus pneumoniae infection.
Qian-qian Du, Wei Shi, Dan Yu, Kai-hu Yao   +3 more
doaj   +2 more sources

Typhoid conjugate vaccine implementation in India: A review of supportive evidence [PDF]

Vaccine: X
Background: Typhoid conjugate vaccines are available in the private market in India and are also recommended by the National Technical Advisory Group on Immunisation (NTAGI) for inclusion in India’s Universal Immunisation Programme in 2022 to control and
Vijayalaxmi V. Mogasale, Anish Sinha, Jacob John, Habib Hasan Farooqui, Arindam Ray, Tracey Chantler, Vittal Mogasale, Bhim Gopal Dhoubhadel, W John Edmunds, Andrew Clark, Kaja Abbas   +10 more
doaj   +2 more sources

A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice. [PDF]

PLoS Neglected Tropical Diseases, 2015
BACKGROUND:Vibrio cholerae is the cause of cholera, a severe watery diarrhea. Protection against cholera is serogroup specific. Serogroup specificity is defined by the O-specific polysaccharide (OSP) component of lipopolysaccharide (LPS).
Md Abu Sayeed, Meagan Kelly Bufano, Peng Xu, Grace Eckhoff, Richelle C Charles, Mohammad Murshid Alam, Tania Sultana, Md Rasheduzzaman Rashu, Amanda Berger, Geoffrey Gonzalez-Escobedo, Anjali Mandlik, Taufiqur Rahman Bhuiyan, Daniel T Leung, Regina C LaRocque, Jason B Harris, Stephen B Calderwood, Firdausi Qadri, W F Vann, Pavol Kováč, Edward T Ryan   +19 more
doaj   +2 more sources

Conjugate vaccines [PDF]

Archives of Disease in Childhood, 2005
Finn, A, Heath, P
core   +5 more sources

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands

Emerging Infectious Diseases, 2015
Three years after a 7-valent pneumococcal conjugate vaccine was replaced by a 10-valent pneumococcal conjugate vaccine in the Netherlands, we observed a decrease in incidence of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1,
Mirjam J. Knol, Gertjan H.J. Wagenvoort, Elisabeth A.M. Sanders, Karin Elberse, Bart J. Vlaminckx, Hester E. de Melker, Arie van der Ende   +6 more
doaj   +2 more sources

Multi-serotype pneumococcal nasopharyngeal carriage prevalence in vaccine naïve Nepalese children, assessed using molecular serotyping. [PDF]

, 2015
Invasive pneumococcal disease is one of the major causes of death in young children in resource poor countries. Nasopharyngeal carriage studies provide insight into the local prevalence of circulating pneumococcal serotypes.
Adhikari, N, Gould, KA, Gurung, M, Hinds, J, Kandasamy, R, Kelly, DF, Murdoch, DR, Ndimah, S, Pollard, AJ, Shrestha, S, Thapa, A, Thorson, S, Waldron, DE   +12 more
core   +21 more sources

Conjugate vaccines [PDF]

Clinical and Experimental Immunology, 2000
David Goldblatt
openalex   +5 more sources

Typhoid Fever Surveillance, Incidence Estimates, and Progress Toward Typhoid Conjugate Vaccine Introduction — Worldwide, 2018–2022

MMWR. Morbidity and mortality weekly report, 2023
Typhoid fever, an acute febrile illness caused by Salmonella enterica serovar Typhi (S. Typhi), is endemic in many low- and middle-income countries† (1).
Molly Hancuh, J. Walldorf, Anna A. Minta, C. Tévi-Bénissan, K. Christian, Yoann Nedelec, K. Heitzinger, M. Mikoleit, A. Tiffany, A. Bentsi-Enchill, L. Breakwell   +10 more
semanticscholar   +1 more source

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

MMWR. Morbidity and mortality weekly report, 2022
In 2021, 20-valent pneumococcal conjugate vaccine (PCV) (PCV20) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.) and 15-valent PCV (PCV15) (Merck Sharp & Dohme Corp.) were licensed by the Food and Drug Administration for adults aged ≥18 years ...
Miwako Kobayashi, Jennifer L. Farrar, R. Gierke, Amadea Britton, L. Childs, A. Leidner, D. Campos-Outcalt, Rebecca L Morgan, Sarah S. Long, H. Talbot, K. Poehling, T. Pilishvili   +11 more
semanticscholar   +1 more source

Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

MMWR. Morbidity and mortality weekly report, 2022
The 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer, Inc]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Merck Sharp & Dohme LLC]) have been recommended for U.S.
Miwako Kobayashi, Jennifer L. Farrar, R. Gierke, A. Leidner, D. Campos-Outcalt, Rebecca L Morgan, S. Long, K. Poehling, A. Cohen, K. Poehling, S. Long, J. Kelman, Lucia Lee, Tina Mongeau, T. Weiser, Uzo Chukwuma, Kristina Lu, M. Makhene, Lynn Fisher, Mark Sawyer, Jason Goldman, D. Nace, Emily Messerli, Elissa Abrams, Aleksandra K. Wierzbowski, Carol Baker, James McAuley, W. Schaffner, Virginia Cane, D. Campos-Outcalt, M. Farley, K. Klugman, Rebecca L Morgan, A. Reingold, L. Rubin, C. Whitney, R. Zimmerman, Emma K. Accorsi, Alison P. Albert, Shriya Bhatnagar, L. Childs, M. Fischer, R. Gorwitz, Angela J. Jiles, Heidi L Moline, P. Moro, Chukwuebuka Nsofor, N. Prasad, H. Walker, Jacquline Risalvato, S. Schillie   +50 more
semanticscholar   +1 more source